Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference took place in San Diego, CA, on December 1-4, 2025. This meeting brought together experts to share the latest updates in dementia research. Check out our exclusive coverage below.

CTAD 2025

The 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
01–04 December 2025 | San Diego, CA

CTAD 2025

The 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
01–04 December 2025 | San Diego, CA
The 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference took place in San Diego, CA, on December 1-4, 2025. This meeting brought together experts to share the latest updates in dementia research. Check out our exclusive coverage below.
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer’s disease 3:00
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer’s disease
Gemma Salvadó • 12 Dec 2025
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease 3:25
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease
Gemma Salvadó • 12 Dec 2025
The biological staging of AD using blood-based biomarkers: combining p-tau217 and MTBR-tau243 2:41
The biological staging of AD using blood-based biomarkers: combining p-tau217 and MTBR-tau243
Gemma Salvadó • 12 Dec 2025
Efficacy and safety of mirodenafil in mild-to-moderate Alzheimer’s disease: Phase II findings 1:44
Efficacy and safety of mirodenafil in mild-to-moderate Alzheimer’s disease: Phase II findings
Sharon Sha • 9 Dec 2025
Update on the ongoing Phase III POLARIS-AD trial of mirodenafil in MCI or mild dementia due to AD 1:37
Update on the ongoing Phase III POLARIS-AD trial of mirodenafil in MCI or mild dementia due to AD
Sharon Sha • 9 Dec 2025
Comorbidities in Alzheimer’s disease: prevalence and therapeutic strategies 2:20
Comorbidities in Alzheimer’s disease: prevalence and therapeutic strategies
Vidyani Suryadevara • 27 Nov 2025
Bone and senescence biomarkers in the plasma of patients with MCI and AD 3:55
Bone and senescence biomarkers in the plasma of patients with MCI and AD
Vidyani Suryadevara • 27 Nov 2025
The potential of PDE5 inhibitors in AD: evidence from mouse models and retrospective studies 2:21
The potential of PDE5 inhibitors in AD: evidence from mouse models and retrospective studies
Sharon Sha • 9 Dec 2025
Results from the Phase IIb trial of neflamapimod in dementia with Lewy bodies 5:11
Results from the Phase IIb trial of neflamapimod in dementia with Lewy bodies
James Galvin • 9 Dec 2025
The development of plasma biomarker clocks to predict AD symptom onset 4:51
The development of plasma biomarker clocks to predict AD symptom onset
Suzanne Schindler • 9 Dec 2025
The development and use of biomarkers for combination therapy in Alzheimer’s disease 4:53
The development and use of biomarkers for combination therapy in Alzheimer’s disease
Suzanne Schindler • 9 Dec 2025
Integrating advancements in blood biomarkers for neurodegenerative diseases into primary care 3:24
Integrating advancements in blood biomarkers for neurodegenerative diseases into primary care
Sid O’Bryant • 10 Dec 2025
The Health & Aging Brain Study: understanding brain health and aging to achieve precision medicine 2:56
The Health & Aging Brain Study: understanding brain health and aging to achieve precision medicine
Sid O’Bryant • 10 Dec 2025
Barriers and strategies to ensure equitable participation in Alzheimer’s disease clinical trials 2:48
Barriers and strategies to ensure equitable participation in Alzheimer’s disease clinical trials
Sid O’Bryant • 10 Dec 2025
Combining digital and blood-based biomarkers to improve AD screening and clinical trial enrollment 5:30
Combining digital and blood-based biomarkers to improve AD screening and clinical trial enrollment
James Galvin • 9 Dec 2025
The association between neurofibrillary tangles and fluid biomarkers of Alzheimer’s disease 2:41
The association between neurofibrillary tangles and fluid biomarkers of Alzheimer’s disease
Mahnaz Shekari • 8 Dec 2025

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals